February 20-22, 2020 | New York Hilton Midtown, NY

Psychedelic Research: Implications for Palliative Care and End-of-Life Existential Distress

Feb 21 2020
10:45 am - 12:00 pm
Anthony Bossis PhD

This presentation will review findings and implications from FDA-approved research with the naturally occurring psychedelic compound psilocybin. The NYU School of Medicine clinical trial demonstrated efficacy of a single psilocybin-generated mystical experience in helping individuals with cancer cultivate meaning, enhance existential and psycho-spiritual well-being, and foster a greater acceptance of the dying process with less anxiety. The landmark 2016 findings of a rapid decrease in depression, anxiety, hopelessness, and demoralization along with improvements in spiritual well-being will be presented. A review of existential distress in end-of-life care will be presented along with a review of the phenomenology of mystical experience and the implications for the study of meaning, spirituality and consciousness research.

Learning Objectives:
  1. Participants will be able to identify factors and symptoms in existential and psycho-spiritual distress in palliative and end-of-life care.
  2. Participants will be able to recognize the importance of meaning and transcendence in end-of-life distress and in psychedelic research.
  3. Participants will be able to describe the characteristics of mystical experience; summarize the scientific findings from current psilocybin cancer anxiety research.
  4. Participants will be able to identify clinical implications from psychedelic research for palliative/hospice care.
Track Name: IHS NY 2020
Session Date: Feb 21 2020 10:45 am – 12:00 pm
© Diversified Communications. All rights reserved.